30 07, 2021

Some Teenagers At Risk Of Self-Harming Can Be Identified A Decade In Advance

By |2021-07-30T04:21:28-07:00July 30th, 2021|Brief Bulletins from the Field, Featured, We Know Psychiatry|0 Comments

There are multiple risk factors for self-harm, including a history of abuse, trauma, physical and mental illness, and bullying. Identifying these factors is a key part of prevention, ensuring that those at risk receive appropriate support as early as possible — but despite this, predicting who may end up engaging [...]

6 05, 2021

FDA Reviewers: Why We Are Against Approval of Aducanumab for Alzheimer’s

By |2021-05-06T09:35:36-07:00May 6th, 2021|Brief Bulletins from the Field, Featured, We Know Psychiatry|0 Comments

Three members of a US Food and Drug Administration (FDA) advisory committee are explaining why they do not support approval of the drug aducanumab (Biogen, Eisai) for the treatment of Alzheimer's disease (AD). G. Caleb Alexander, MD, Scott Emerson, MD, PhD, and Aaron Kesselheim, MD, JD, MPH, all serve on the [...]

6 05, 2021

Novel Drug Offers Rapid Relief From Agitation in Serious Mental Illness

By |2021-05-06T09:36:50-07:00May 6th, 2021|Brief Bulletins from the Field, Featured, We Know Psychiatry|0 Comments

An investigational, orally dissolving film formulation of dexmedetomidine (BXCL501, BioXcel Therapeutics) may offer rapid relief from acute agitation related to schizophrenia or bipolar disorder (BD), results of two phase 3, randomized, placebo-controlled trials show. Dr Leslie Citrome For both disorders, BXCL501 showed "superiority over placebo" by meeting the primary endpoint of reduction of agitation as [...]

19 01, 2021

Associations between breast cancer survivorship and adverse mental health outcomes: A matched population-based cohort study in the United Kingdom

By |2021-01-19T12:45:20-08:00January 19th, 2021|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

SUMMARY In this study, we observed that compared to women with no prior cancer, breast cancer survivors had higher risk of anxiety, depression, sleep problems, sexual dysfunction, fatigue, receipt of opioid analgesics, and pain. Relative risks estimates tended to decrease over time, but anxiety and depression were significantly increased for [...]

20 10, 2020

Suicide Prevention in the COVID-19 Era Transforming Threat Into Opportunity

By |2020-10-20T09:07:02-07:00October 20th, 2020|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

From: JAMA Psychiatry. Published online October 16, 2020. doi:10.1001/jamapsychiatry.2020.3746 By Christine Moutier, MD Introduction International and US experts on suicide have expressed concerns about the potential the coronavirus disease 2019 (COVID-19) pandemic has to increase the risk of suicide through its effects on a number of well-established suicide risk factors.1,2 Suicide surveillance [...]

6 08, 2020

CBD Can Improve Mental and Physical Health

By |2020-10-02T11:42:02-07:00August 6th, 2020|Brief Bulletins from the Field, Featured|6 Comments

With a vast range of medical and therapeutic benefits, CBD, or cannabidiol, is a derivative of the hemp plant. Researches have supported the claims that CBD may be a potential natural alternative to several traditional medicines. Consequently, CBD has become an ever-increasing industry. From pain-relieving balms to skin serums and [...]

29 07, 2020

A Comprehensive Update of Lofexidine for the Management of Opioid Withdrawal Symptoms

By |2020-07-29T09:04:39-07:00July 29th, 2020|Brief Bulletins from the Field|0 Comments

The current maintenance treatment for opiate withdrawal usually includes using a different, controlled, opiate, either methadone or buprenorphine. Alpha-2 receptor agonists, such as lofexidine, can be used to manage the acute symptoms during withdrawal. Lofexidine is effective and safe and is FDA approved for the management of withdrawal symptoms. It [...]

29 07, 2020

Naldemedine for the Use of Management of Opioid Induced Constipation

By |2020-07-29T08:59:49-07:00July 29th, 2020|Brief Bulletins from the Field|0 Comments

According to Urits and Viswanath, Opioid medications are fundamental in anesthesia and analgesia and are often used to treat acute and chronic pain. They achieve their desired effects by modulating pain perception in the central nervous system; however, they also act on opioid receptors in the periphery, causing many undesirable [...]

Title

Go to Top